Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 407–414.

https://doi.org/10.1182/hematology.2019000048

Published: 2019

Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.

https://doi.org/10.1182/asheducation-2017.1.480

Published: 2017

Journal Articles

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Deepti Radia, Holly L. Geyer

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 340–348.

https://doi.org/10.1182/asheducation-2015.1.340

Published: 2015

Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.

https://doi.org/10.1182/asheducation-2014.1.277

Published: 2014

Journal Articles

Management of MPN beyond JAK2

Claire N. Harrison, Natalia Curto Garcia

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 348–354.

https://doi.org/10.1182/asheducation-2014.1.348

Published: 2014

Journal Articles

The spectrum of JAK2-positive myeloproliferative neoplasms

Jean-Jacques Kiladjian

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 561–566.

https://doi.org/10.1182/asheducation.V2012.1.561.3807838

Published: 2012

Journal Articles

Thrombotic disease in the myeloproliferative neoplasms

Anna Falanga, Marina Marchetti

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 571–581.

https://doi.org/10.1182/asheducation.V2012.1.571.3798557

Published: 2012

Journal Articles

Management of Myelofibrosis

Alessandro M. Vannucchi

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 222–230.

https://doi.org/10.1182/asheducation-2011.1.222

Published: 2011

Journal Articles

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants

James Vardiman, Elizabeth Hyjek

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 250–256.

https://doi.org/10.1182/asheducation-2011.1.250

Published: 2011

Journal Articles

Management of Essential Thrombocythemia

Francisco Cervantes

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 215–221.

https://doi.org/10.1182/asheducation-2011.1.215

Published: 2011

Journal Articles

Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera

Claire Harrison

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 129–134.

https://doi.org/10.1182/asheducation-2010.1.129

Published: 2010

Journal Articles

Pathogenesis and management of essential thrombocythemia

Philip A. Beer, Anthony R. Green

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 621–628.

https://doi.org/10.1182/asheducation-2009.1.621

Published: 2009

Journal Articles

Therapeutic potential of JAK2 inhibitors

Srdan Verstovsek

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636–642.

https://doi.org/10.1182/asheducation-2009.1.636

Published: 2009

Journal Articles

New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia

Ross L. Levine, Mark Heaney

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 76–82.

https://doi.org/10.1182/asheducation-2008.1.76

Published: 2008

Journal Articles

Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders

Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 355–362.

https://doi.org/10.1182/asheducation-2007.1.355

Published: 2007

Journal Articles

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders

Ross L. Levine, Gerlinde Wernig

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 233–239.

https://doi.org/10.1182/asheducation-2006.1.233

Published: 2006

Journal Articles

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2 V617F Era

Ayalew Tefferi

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 240–245.

https://doi.org/10.1182/asheducation-2006.1.240

Published: 2006

Journal Articles

Acquired Disorders of Platelet Function

Amy A. Hassan, Michael H. Kroll

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 403–408.

https://doi.org/10.1182/asheducation-2005.1.403

Published: 2005

Journal Articles

A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases

William Vainchenker, Stefan N. Constantinescu

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 195–200.

https://doi.org/10.1182/asheducation-2005.1.195

Published: 2005

Journal Articles

Management of Polycythemia Vera and Essential Thrombocythemia

Peter J. Campbell, Anthony R. Green

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 201–208.

https://doi.org/10.1182/asheducation-2005.1.201

Published: 2005

NARROW

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Management of MPN beyond JAK2

The spectrum of JAK2-positive myeloproliferative neoplasms

Thrombotic disease in the myeloproliferative neoplasms

Management of Myelofibrosis

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants

Management of Essential Thrombocythemia

Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera

Pathogenesis and management of essential thrombocythemia

Therapeutic potential of JAK2 inhibitors

New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia

Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2 V617F Era

Acquired Disorders of Platelet Function

A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases

Management of Polycythemia Vera and Essential Thrombocythemia

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only